Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2015

View Archived Issues

Heat Biologics begins trial combining HS-110 and PD-1 checkpoint inhibitor in NSCLC

Corbus initiates phase II trial of Resunab for systemic sclerosis

Daktari Diagnostics and Merck & Co. to collaborate on point-of-care HCV test

Ono Pharmaceuticals presents EP2 receptor agonists

RXi Pharmaceuticals plans clinical studies of RXI-109 in ophthalmic scarring

Essex Bio-Technology and Tasly Pharmaceutical collaborate on recombinant protein drugs

Viking Therapeutics begins trial of VK-5211 for acute hip fracture

Amgen and Novartis establish neuroscience collaboration in Alzheimer's disease and migraine

CHDI-003402346, a new clinical candidate for HD

Dicerna Pharmaceuticals submits IND application to FDA for DCR-PH1

FDA approves Varubi for nausea and vomiting associated with cancer chemotherapy

GS-6615 shows short-term efficacy for the treatment of arrhythmia

FDA grants orphan drug designation to LOXO-101

Nissan Chemical Industries ends license agreement with Teijin Pharma and BMS for NTC-801

Novartis receives E.U. approval for Revolade in severe aplastic anemia

Bristol-Myers Squibb discloses anti-HIV macrocycles

Janssen introduces anti-HBV agents

Takeda introduces enteropeptidase inhibitors

Merck KGaA divulges dual p70S6K/Akt inhibitors

Incyte patents LSD1 inhibitors

Suven's 5-HT4 receptor agonist for cognitive dysfunction enters phase I

Avycaz demonstrates efficacy in phase III trial in cUTI

Amgen files MAA for etelcalcetide in secondary hyperparathyroidism

Reduced dose of IL-37 attenuates arterial calcification

FDA grants fast track designation to intravenous iclaprim

FDA issues new approval for Emend

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...